Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Sildenafil Tablets 100mg (Pharmtechnology LLC, Belarus) and Viagra® Tablets 100mg (Fareva Amboise, France) in Healthy Male Volunteers Under Fasting Conditions

NCT04882826 is registered in ClinicalTrials.gov with Pharmtechnology LLC as lead sponsor.

NCT NCT04882826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04882826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Sildenafil Tablets 100mg (Pharmtechnology LLC, Belarus) and Viagra® Tablets 100mg (Fareva Amboise, France) in Healthy Male Volunteers Under Fasting Conditions
Lead sponsor
Pharmtechnology LLC
Phase
Phase 1
Overall status
Unknown status
Start date
May 10, 2021
Completion date
May 30, 2021
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence